News | Hemodynamic Support Devices | April 12, 2018

CorWave Awarded Second Round of Financing for Mini-Invasive Cardiac Support Pump

NovaPulse program developing new type of partial support small enough to fit into an envelope the size of an implantable defibrillator

April 12, 2018 – French medical technology company CorWave announced it has been awarded almost $3.5 million in financing for its R&D program NovaPulse in the Silver Economy category. This is part of phase 2 of France’s Concours Mondial d'Innovation or Worldwide Innovation Challenge.

With this new financing, CorWave will be able to step up the pace of development of NovaPulse, a new mini-invasive cardiac support pump, and thereby improve the care of older patients suffering from chronic heart failure, one of the leading causes of death worldwide.

The aim of the Worldwide Innovation Challenge is to foster talent and pave the way for the emergence of France’s future economic champions. The challenge is financed by the Invest for the Future Program (PIA) and managed by Bpifrance.

CorWave CEO Louis de Lillers explained the NovaPulse program paves the way for less invasive implantation of cardiac support devices, particularly for older patients who are often too weak for open heart surgery. The NovaPulse program is focused on the development of CorWave Nemo, a partial support device, complementary to CorWave Neptune, the company’s full support left ventricular assist device (LVAD).

CorWave was already a winner in phase 1 of the Worldwide Innovation Challenge in July 2016. This gave CorWave the resources to identify and establish the technological proof-of-concept required to provide a new type of partial support, small enough to fit into an envelope the size of an implantable defibrillator.  It has since raised €15.5 million in funding from Novo Seeds, Ysio Capital and from its historic investors, Sofinnova Partners, Bpifrance and Seventure, which had already invested €3.3 million in the company in 2013.

In 2017, almost 10,000 cardiac support devices were implanted worldwide, a small number in relation to the number of people suffering from heart failure. A high level of complications is holding this therapy back: Two years after implantation, four patients out of five are affected by at least one severe complication caused by the pump. The pumps currently on the market function in a very different way to the human heart. They cause a number of physiological imbalances, leaving the door open to complications.

CorWave’s technology’s undulating wave pumps reproduce the operation of the human heart and should therefore reduce complications. This progress would enable wider adoption of implantable cardiac support devices, which already represent a market of almost $1 billion in annual sales.

For more information: www.corwave.fr

 

Related Content

Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Videos | Heart Failure | March 23, 2018
David Lanfear M.D., FACC, head of advanced heart failure and cardiac transplantation, Henry Ford Hospital, Detroit, d
Guideline Adherence, Not Patient Volume, May Be Better Hospital Heart Failure Metric
News | Heart Failure | February 01, 2018
February 1, 2018 –  In evaluating the quality of care given to those hospitalized with...
First-in-Man RenalGuard Studies Show Promise for Heart Failure Patients
News | Heart Failure | January 02, 2018
RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of...
ACC Issues New Guidance to Optimize Heart Failure Treatment
News | Heart Failure | December 22, 2017
December 22, 2017 — To help streamline treatment of patients with...
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure | November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years among U.S. veterans, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.
News | Heart Failure | November 25, 2017
November 25, 2017 — Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years a
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure | November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure | November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
Overlay Init